Smart Immune Doses First Leukemia Patients with ProTcell Therapy SMART101 in ReSET-02 Phase I/II Trial
27 sept. 2023 02h00 HE
|
Smart Immune
No safety concerns in first two patients treatedDesigned to accelerate T-cell reconstitution following haploidentical Hematopoietic Stem Cell Transplantation (HSCT) with post-transplant...
Deux premiers patients atteints de leucémie ont reçu la thérapie SMART101 de Smart Immune dans le cadre de l'essai ReSET-02 de phase I/II
27 sept. 2023 02h00 HE
|
Smart Immune
Aucune toxicité observée chez les deux premiers patients traités SMART101 est conçu pour accélérer la reconstitution immunitaire après une greffe de cellules souches haplo-identique suivie d’un...
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA)
11 mai 2023 11h58 HE
|
Smart Immune
Smart Immune to present details of the phase I/II studies of new T-cell therapy SMART101 at the European Hematology Association (EHA) Two poster presentations at EHA showcase ProTcell, an innovative...
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform
17 avr. 2023 01h00 HE
|
Smart Immune
Smart Immune receives $5 million investment to further its thymus-empowered ProTcell therapy platform The new funding from the Gates Foundation will advance a Phase 1/2 clinical trial of an...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
30 mars 2023 07h00 HE
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator
30 mars 2023 04h24 HE
|
Smart Immune
Smart Immune receives €2.5m grant and €15m equity investment commitment from the European Innovation Council (EIC) via the EIC Accelerator PARIS, France, 30 March, 2023 – Smart Immune SAS, a...
Smart Immune is selected for the first cohort of the French Tech Health20 program
27 mars 2023 07h32 HE
|
Smart Immune
Smart Immune is selected for the first cohort of the French Tech Health20 program This unique program has selected 20 French start-ups that offer disruptive healthcare innovations PARIS, France,...
Smart Immune appoints world-class Clinical Advisory Board
21 nov. 2022 07h00 HE
|
Smart Immune
Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers
13 oct. 2022 07h00 HE
|
Smart Immune
Smart Immune and Greater Paris University Hospitals (AP-HP) begin groundbreaking Phase I/II trial with ProTcellTM, a thymus-empowered T-cell therapy platform, in adults with blood cancers First trial...
Smart Immune Bolsters Management Team with Medical and Technical Appointments
13 sept. 2022 07h00 HE
|
Smart Immune
Smart Immune Bolsters Management Team with Medical and Technical Appointments Dr Frederic Lehmann, MD, appointed Chief Medical Officer and Dr Pierre Heimendinger, PharmD, appointed Chief Technical...